Novavax receives $1.6 billion for potential COVID-19 vaccine under Operation Warp Speed

Novavax is set to receive more than a billion dollars in federal funding for its COVID-19 vaccine candidate.

The company on Tuesday morning announced it's getting $1.6 billion from the Trump administration's Operation Warp Speed, and this money will help it to "complete late-stage clinical development," "establish large-scale manufacturing," and "deliver 100 million doses" of its potential vaccine "as early as late 2020."

The Trump administration's Operation Warp Speed aims to speed up the development of a vaccine for COVID-19, and the $1.6 billion for Novavax is the largest deal the administration has made as part of this program so far, The New York Times reports. Novavax has "never brought a product to market," the Times notes.

Subscribe to The Week

Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

SUBSCRIBE & SAVE

Sign up for The Week's Free Newsletters

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Sign up

"We are grateful to the U.S. government for its confidence in our technology platform, and are working tirelessly to develop and produce a vaccine for this global health crisis," Novavax CEO Stanley C. Erck said.

U.S. Health and Human Services Secretary Alex Azar also said in a statement that backing Novavax's vaccine candidate "increases the odds that we will have a safe, effective vaccine as soon as the end of this year." Novavax says it's planning to begin its phase three clinical trial with up to 30,000 subjects in the fall.